Table 2.
Use of TCR-Tg models for studies of anti-tumor CD4+ T cell immune responses.
| TCR-Tg model (antigen) | Tumor cell line | Ectopic antigen expr.a | MHC II expr. | Antigen secreted? | T cell source | Reference |
|---|---|---|---|---|---|---|
| 4B2A1 (λ2315) | MOPC315 (plasmacytoma) | No | − | Yes | Naïve (endogenous)b | (26, 27, 34, 65) |
| MOPC315.37c | No | − | No | Naive (endogenous) | (36) | |
| A20 (B lymphoma) | Yes | + | Yes | Naive (endogenous) | (26, 33, 66) | |
| Adoptive transfer, naive | ||||||
| A20 (B lymphoma)d | Yes | + | No | Naive (endogenous) | (26) | |
| 7A6 (Trp1) | B16/CIITA (melanoma) | No | +e | N/D | Naive (endogenous) | (35) |
| Adoptive transfer, activated | ||||||
| B16 (melanoma) | No | +f | N/D | Adoptive transfer, naïve | (37, 38) | |
| Adoptive transfer, activated | ||||||
| Marilyn (H–Y) | MB49 (bladder) | No | +f | N/D | Adoptive transfer, naive | (28) |
| TRAMP-C2 (prostate) | No | − | N/D | Adoptive transfer, activated | ||
| βTC-TET | No | − | N/D | |||
| WR21 (salivary gland) | No | − | N/D | |||
| T2.5-5 (HA) | AB1 (mesothelioma) | Yes | − | N/Dg | Naive (endogenous) | (40) |
| Adoptive transfer, naive | ||||||
| 14.3d (HA) | CT26 (colon) | Yes | N/Dh | N/Di | Naive (endogenous) | (41, 42) |
| Adoptive transfer, naive | ||||||
| DO11.10 (OVA) | A20 (B lymphoma) | Yes | + | N/Dj | Adoptive transfer, activated | (17) |
| A20 (B lymphoma) | Yes | + | Nok | Naive (endogenous) | (44) | |
| Adoptive transfer, activated | ||||||
| OT-II (OVA) | EG-7 (thymoma) | Yes | − | Yesl | Adoptive transfer, activated | (43) |
N/D, not determined.
aEctopic antigen expression signifies that the tumor cell line was transfected for expression of the relevant antigen.
bThe designation naive (endogenous) is used to describe tumor challenge experiments in TCR-Tg mice in which no prior priming of antigen-specific T cells was performed.
cMOPC315.37 contains a Gly15 → Arg15 mutation within the λ2 gene that causes intracellular retention (67).
dCells were transfected with a mutated λ2315 variant that causes retention within the endoplasmic reticulum, precluding secretion (67).
eCells were transfected to overexpress MHC class II trans-activator (CIITA) to ensure high levels of expression of MHC II (35).
fInducible expression by interferon gamma stimulation.
gOnly cell surface expression was tested (40).
hA previous publication reports constitutive MHC II expression in vitro (68).
iCells were transfected with HA fused to EGFP. Only surface expression was tested (41).
jSecretion expected; cells were transduced with constructs containing the full-length OVA cDNA sequence, which contains signal element for secretion (58).
kCells were transfected with OVA fused to the trans-membrane domain of transferrin receptor, causing membrane expression (44).
lEarlier report demonstrates secretion from the same cell line (69).